Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1934073 | 0.95 | ELANE (0.42) | MTNR1AMTNR1BHPGDALDH1A1ELANE | |
| SCHEMBL394357 | 0.93 | POLB (0.45) | HPGDELANEPOLBMCL1KCNK3 | |
| SCHEMBL5734309 | 0.93 | POLB (0.45) | HPGDELANEPOLBMCL1KCNK3 | |
| SCHEMBL4425242 | 0.93 | ELANE (0.41) | ALDH1A1ELANE | |
| SCHEMBL12064486 | 0.81 | HRH3 (0.46) | MEN1KMT2A | |
| SCHEMBL29010480 | 0.80 | MAPT (0.46) | HPGDALDH1A1USP2MEN1KMT2A | |
| SCHEMBL29010483 | 0.78 | CHRM2 (0.32) | KMT2A | |
| SCHEMBL23893550 | 0.78 | KDM1A (0.36) | ELANE | |
| SCHEMBL17073070 | 0.78 | ELANE (0.33) | ELANEKMT2A | |
| SCHEMBL18856453 | 0.78 | MEN1 (0.49) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119192226-A | Method for synthesizing photocatalytic organic germanide | 延安大学 | 2024-12-27 | — | — | CN | disclosed |
| CN-116462561-A | Alkylation method of visible light-promoted alkenyl cycloalkane compound | 深圳市鹏泰生物科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-108794308-B | 1,2,3, 4-tetrahydronaphthalene compound and preparation method and application thereof | 北京大学深圳研究生院 | 2021-07-20 | — | — | CN | disclosed |
| US-6835860-B2 | Halogenation with iodine monochloride and iodine monobromide in an aqueous solution, forming a chemical intermediate for the preparation of indinavir, an HIV protease enzyme inhibitor | MERCK & CO., INC. | 2004-12-28 | — | — | US | disclosed |
| US-20030187291-A1 | Halogenation with iodine monochloride and iodine monobromide in an aqueous solution, forming a chemical intermediate for the preparation of indinavir, an HIV protease enzyme inhibitor | MERCK SHARP & DOHME CORP. | 2003-10-02 | — | — | US | disclosed |
| US-6372911-B1 | REACTING COMPOUND CONTAINING AT LEAST ONE CARBON-CARBON DOUBLE BOND WITH CARBAMATE IN AQUEOUS SOLVENT IN PRESENCE OF BASE, OSMIUM CATALYST, CO-OXIDANT, AND OPTIONALLY ASYMMETRIC LIGAND, TO FORM REACTION MIXTURE CONTAINING BETA-HYDROXY CARBAMATE | MERCK & CO., INC. | 2002-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187291-A1 | Halogenation with iodine monochloride and iodine monobromide in an aqueous solution, forming a chemical intermediate for the preparation of indinavir, an HIV protease enzyme inhibitor | IDE, MMP1, CYP3A4 | MTNR1A 4198/4885MTNR1B 3155/4885ATM 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.